Small Cap Feast

11th January 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings:



Whats baking in the oven?

Potential Initial Public Offerings:


Reverse Takeovers:


Change of Market:


Banquet Buffet

Abingdon Health 10.25p £12.5m (ABDX.L)
A international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months ended 31 December 2023. Revenues increased by 118% to £2.4m (H1 2022/3 £1.1m). Driven by the Company's contract service customer base across lateral flow research & development. Cash at 31 December 2023 was £1.9m (30 June 2023: £3.2m). The Board confirms the promotion of Laura Towse, who has been with the business since June 2023, to Group Financial Controller effective 1 January 2024 and Andrew Feather, interim Finance Director, will leave the business in January 2024. The Company look forward into H2 2023/4 in confidence.

CyanConnode Holdings 12p £38.8m (CYAN.L)
A Company focusing on narrowband radio frequency (RF) mesh networks, announces that its subsidiary, CyanConnode Pvt Ltd, has received an order from Montecarlo Limited (Montecarlo) for one million Omnimesh Modules, together with Advanced Metering Infrastructure, Standards-Based Hardware, Omnimesh Head-End Software, Perpetual License, and a Support and Maintenance Contract. The order relates to a smart metering deployment in Nagpur, Maharashtra, with supply of Omnimesh Modules expected to commence within this quarter. This order boosts the Company’s total Indian order book to 6.3 million units, with 3.9 million modules scheduled for delivery in accordance with the established project timelines.

Essensys 36.5p £23.6m (ESYS.L)
The provider of software and technology to the flexible workspace industry, announces that Sarah Harvey, Chief Financial Officer, has decided to resign from the Board of essensys. Sarah joined essensys' Board in May 2022 and will continue as Chief Financial Officer and a director of the Company until a successor is appointed to ensure a smooth handover. A search is underway to identify and appoint a successor and the Company will provide an update in due course.

Kibo Energy* 0.034p £1.3m (KIBO.L)
The renewable energy-focused development company announces that it has received a conversion notice (Conversion Notice) under the terms of the facility agreement signed between the Company and RiverFort Global Opportunities PCC Limited (RiverFort). As per the Conversion Notice, the Company has today allotted 500,000,000 new ordinary Kibo shares of EUR0.0001 each to RiverFort representing conversion of accrued fees and interest totalling £161k owing to RiverFort. The Company further announces that Mr. Ajay Saldanha has retired as a non-executive director of the Company with effect from 10 January 2024. The Company is in the process of identifying a replacement independent non-executive director. The Company announces that its current Chief Financial Officer, Mr. Jacobus (Cobus) van der Merwe, has, subject to the completion of regulatory checks, agreed to join the board. Mr. van der Merwe will continue as a member of the executive management team of the Company in his new position as Financial Director.

Knights Group Holdings 126.25p £108.3m (KGH.L)
A legal and professional services business in the UK, announces its half year results for the six months ended 31 October 2023. Revenue up 6% to £75.3m (H1 FY23: £71.2m), in line with Board expectations, as a result underlying EBITDA of 25% to £18.2m (H1 FY23: £14.6m). Net debt increased to £38.3m, (H1 FY23: £35.6m, FY23: £29.2m) after a cash outlay of c.£7.5m relating to acquisition consideration and related non underlying costs. The Company expanded presence in the North, with acquisitions of St James' Law in Newcastle and Baines Wilson in Carlisle which have integrated well and are performing as expected. Trading continued in line with Board’s expectations.

Microlise Group 102.5p £118.8m (SAAS.L)
A provider of SaaS based transport technology solutions to fleet operators, announces it has completed the acquisition of the entire issued share capital of Enterprise Software Systems (ESS). On 30 November 2023, the Company announced it had entered into an agreement for a maximum consideration of £8.5m in cash, funded by the Company's cash reserves. For the 12 months to 31 August 2023, ESS generated revenues of approximately £5.1m and adjusted EBITDA of £1m, with approximately 75 per cent of the revenue being recurring, based on long-term contracts.

Mpac Group 290p £59.4m (MPAC.L)
A Company focusing on high-speed packaging and automation solutions, announces a trading update (unaudited) for the year ended 31 December 2023 (FY23). As anticipated, revenue and profit before tax in H2 2023 were above H1 2023, aided by the normalisation of margins through 2023. Order intake remained strong for the Group and ended FY23 with an increased value of the closing order book at c.£75.0m (FY22: £67.2m) providing good coverage of 2024 forecast revenue. The Board announces that the Group is well placed to deliver on the expectations and long term growth strategy.

MyHealthChecked 14.25p £7.4m (MHC.L)
The consumer home-testing healthcare company, provides an update on trading for the year ended 31 December 2023. The Board is expecting EBITDA for the full year to be around breakeven of c£0.1m (H1: £0.3m loss; FY 2022: £2.3m profit). Revenue for the full year amounted to approximately £11m (H1: £2.5m, 2022 FY: £22.3m) due to the increased seasonal demand for COVID lateral flow tests during H2. As the working capital requirement has been carefully managed cash at the year-end has also increased to £7.75m (H1: £5.0m, FY 2022: £7.61m). The Board further announce that it has traded profitably during the second half of the year, whilst continuing to invest in the development of the new product range.

UK Oil & Gas 0.026p £6.2m (UKOG.L)
The UK-based oil and gas exploration and production company announces that following the successful completion of repair and strengthening of the access track and well pad. The Company are advised by operator AME that perforating operations should commence towards the end of next week or by the following Monday, 22 January 2024. PSI, the service provider of the new 7-inch perforating guns, capable of fully penetrating Pinarova's 9⅝-inch casing, has now been mobilised and their wireline-conveyed perforating operations can start in line with the above schedule. UKOG holds a 50% non-operated interest in Pinarova-1 and the surrounding 305 km² Resan licence, which also includes the as yet undeveloped Basur-1 light oil discovery.

Windward 104p £89.1m (WNWD.L)
A Maritime AI company, provides an update on trading for the year ended 31 December 2023 (FY2023). Revenue is expected to have increased by 31% to approximately $28.3m (FY2022: $21.6m), and adjusted EBITDA loss to have reduced considerably to approximately $5.1m (FY2022: $12.1m). Customer numbers increased strongly in the year, now exceeding 200 (31 December 2022: 132). As a result, the Group's Annual Contract Value (ACV1) as at 31 December 2023 increased by 35% to $34.5m. The Board reports it expects FY2023 results to be ahead of market forecasts.

11 January 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram